<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>05391536010256</udiDi>
    <basicUdiDi>843659383XIA643NC</basicUdiDi>
    <tradeName>Tasectan AF</tradeName>
    <deviceName>XILAPLUS AF sachets without flavour</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR APPETITE CONTROL AND REDUCTION OF INTESTINAL ABSORPTION</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1312070</reference>
    <placedOnMarketCountry>Ireland</placedOnMarketCountry>
    <lastUpdated>2026-07-03T11:50:34.452Z</lastUpdated>
  </row>
  <row>
    <udiDi>08436593831349</udiDi>
    <basicUdiDi>843659383UTA433QH</basicUdiDi>
    <tradeName>Utipro Plus AF</tradeName>
    <deviceName>Utipro Plus AF tablets</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0499</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED GASTROINTESTINAL DEVICES - OTHER</emdnDescription>
    <deviceStatus>AB pazarı için değil</deviceStatus>
    <reference>000000</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:33:41.165Z</lastUpdated>
  </row>
  <row>
    <udiDi>08436593831271</udiDi>
    <basicUdiDi>843659383XIA623N6</basicUdiDi>
    <tradeName>Direxol</tradeName>
    <deviceName>XILAPLUS AF capsules</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1313112</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:33:39.960Z</lastUpdated>
  </row>
  <row>
    <udiDi>08436593830625</udiDi>
    <basicUdiDi>843659383XIA633N9</basicUdiDi>
    <tradeName>Xilaplus AF sobres sin aroma</tradeName>
    <deviceName>Xilaplus AF sachets with flavour</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0402</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR APPETITE CONTROL AND REDUCTION OF INTESTINAL ABSORPTION</emdnDescription>
    <deviceStatus>AB pazarı için değil</deviceStatus>
    <reference>1310678</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:33:32.750Z</lastUpdated>
  </row>
  <row>
    <udiDi>08436593830052</udiDi>
    <basicUdiDi>843659383XIA653NF</basicUdiDi>
    <tradeName>Xilaplus AF comprimidos</tradeName>
    <deviceName>Xilaplus AF tablets</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0402</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR APPETITE CONTROL AND REDUCTION OF INTESTINAL ABSORPTION</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1291414</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:33:19.555Z</lastUpdated>
  </row>
  <row>
    <udiDi>08006540717158</udiDi>
    <basicUdiDi>843659383UTA423QE</basicUdiDi>
    <tradeName>URI-CRAN FORTE  AF 15 capsules</tradeName>
    <deviceName>UTIPRO PLUS AF capsules</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0499</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED GASTROINTESTINAL DEVICES - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1311830</reference>
    <placedOnMarketCountry>Belgium</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:23:22.162Z</lastUpdated>
  </row>
</eudamedExport>